To Evaluate the Efficacy, Safety, and Tolerability of BBT-877 in Patients With IPF
Status:
Not yet recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled, study to
evaluate the efficacy, safety, and tolerability of 200 mg twice daily (BID) of BBT-877 in
patients with IPF, with or without AF approved background therapies (pirfenidone or
nintedanib).